Bausch Health Companies (BHCN) AI Stock Analysis

Company Guidance

For full-year 2026, revenue is expected to be between $5.525 billion and $5.625 billion, with the midpoint translating to an 8% increase year over year; adjusted EBITDA is expected to be between $3.225 billion and $3.275 billion, with the midpoint representing a 13% increase versus 2025; and adjusted cash flow from operations is expected to be between $1.6 billion and $1.675 billion, with the mid point translating to a 29% increase year over year. The company increased the midpoint of its full year guidance by $150 million for revenue, approximately $190 million for adjusted EBITDA and $200 million for adjusted cash flow from operations. Q4 guidance includes an 800 basis points of revenue growth reduction and 1.4 thousand basis points of adjusted EBITDA growth reductions from the Xifaxan gross to net accrual, plus at least another 300 basis points of growth reduction and 500 basis points of adjusted EBITDA reduction from normalization of Xifaxan channel inventory; Solta is expected to be in the mid-single-digits for overall SALTA on an organic basis in Q4. The implicit guidance provided for 2027 is about $2.7 billion, with the net impact of all the puts and takes around $400 million to $500 million year over year.